$112 million Series B financing for Neumora

Neumora Therapeutics, a US clinical-stage biotech focussed on brain diseases through the integration of data science and neuroscience that came out of stealth in July last year with $500 million financing, has added to its cash pile announcing today the close of a $112 million Series B financing.

The Series B syndicate includes both new and existing investors, such as Abu Dhabi Growth Fund (ADG), Altitude Life Science Ventures, Amgen, ARCH Venture Partners, Exor Ventures, F-Prime Capital, Invus, Mubadala Capital, Newpath Partners, Polaris Partners and other undisclosed investors.

The funding will support the advancement of a broad clinical and pre-clinical pipeline of novel precision medicine candidates for neuropsychiatric disorders and neurodegenerative diseases and the development of the company's precision neuroscience platform.

“This Series B financing reflects Neumora’s continued progress in building a best-in-class neuroscience company, including assembling a world-class team, scaling up an industry-leading data science and translational neuroscience platform, and advancing a broad and growing pipeline of seven development programs, including our internal discovery efforts and business development activities,” said Paul Berns, co-founder, chairman and chief executive of Neumora, adding: “This considerable amount of progress in such a short period of time reflects our urgency to address the relative lack of progress and innovation in neuroscience with our data-driven, precision medicine approach.”